GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis

Circulation Research

Volumn 119, Issue 11, 2016, Pages 1242-1253

  Joshi, Aditya A ^a,b   Lerman, Joseph B ^a   Aberra, Tsion M ^a   Afshar, Mehdi ^c   Teague, Heather L ^a   Rodante, Justin A ^a   Krishnamoorthy, Parasuram ^d   Ng, Qimin ^a   Aridi, Tarek Z ^a   Salahuddin, Taufiq ^a,e   Natarajan, Balaji ^a,f   Lockshin, Benjamin N ^g   Ahlman, Mark A ^h   Chen, Marcus Y ^a   Rader, Daniel J ⁱ   Reilly, Muredach P ^k   Remaley, Alan T ^a   Bluemke, David A ^a   Playford, Martin P ^a   Gelfand, Joel M ^j   Mehta, Nehal N ^a   more..

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d ALBERT EINSTEIN MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^g DermAssociates PC   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

cardiovascular disease; coronary artery disease; FDG PET CT; GlycA; inflammation; psoriasis; risk factors

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLYCA PROTEIN; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 16; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 4; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; AUTACOID;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; VASCULITIS; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; CROSS-SECTIONAL STUDY;

ADULT; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS;

EID: 84991476704     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309637     Document Type: Article

References (38)

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013. doi: 10.1056/ NEJMra1216063.
2. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138. doi: 10.1016/j. jacc.2009.09.009.
3. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148:S19-S26. doi: 10.1016/j.ahj.2004.04.028.
4. Ritchie SC, Würtz P, Nath AP, et al. The biomarker glyca is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 2015;1:293-301. doi: 10.1016/j.cels.2015.09.007.
5. Emami H, Vijayakumar J, Subramanian S, Vucic E, Singh P, MacNabb MH, Corsini E, Hoffmann U, Bathon JM, Solomon DH, Tawakol A. Arterial 18F-FDG uptake in rheumatoid arthritis correlates with synovial activity. JACC Cardiovasc Imaging. 2014;7:959-960. doi: 10.1016/j. jcmg.2014.03.018.
6. Kay SD, Poulsen MK, Diederichsen AC, Voss A. Coronary, carotid, and lower-extremity atherosclerosis and their interrelationship in danish patients with systemic lupus erythematosus. J Rheumatol. 2016;43:315-322. doi: 10.3899/jrheum.150488.
7. Staniak HL, Bittencourt MS, de Souza Santos I, Sharovsky R, Sabbag C, Goulart AC, Lotufo PA, Benseñor IM. Association between psoriasis and coronary calcium score. Atherosclerosis. 2014;237:847-852. doi: 10.1016/j.atherosclerosis.2014.11.004.
8. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA. 2012;308:379-386. doi: 10.1001/jama.2012.6698.
9. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987;215:311-315.
10. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61:714-723. doi: 10.1373/clinchem.2014.232918.
11. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3:e001221. doi: 10.1161/JAHA.114.001221.
12. Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the predictive value of glyca and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62:1020-1031. doi: 10.1373/clinchem.2016.255828.
13. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:1544-1550. doi: 10.1161/ ATVBAHA.115.305635.
14. Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, Bakker SJ, Otvos JD, Dullaart RP. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2016;452:10-17. doi: 10.1016/j. cca.2015.11.001.
15. Bartlett DB, Connelly MA, AbouAssi H, Bateman LA, Tune KN, Huebner JL, Kraus VB, Winegar DA, Otvos JD, Kraus WE, Huffman KM. A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Res Ther. 2015;18:86. doi: 10.1186/s13075-016-0982-5.
16. Chung CP, Ormseth MJ, Connelly MA, Oeser A, Solus JF, Otvos JD, Raggi P, Stein CM. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016;25:296-300. doi: 10.1177/0961203315617842.
17. Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43:745-750. doi: 10.3899/jrheum.150437.
18. Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther. 2015;17:117. doi: 10.1186/ s13075-015-0646-x.
19. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512-516. doi: 10.1016/j.jaad.2013.11.013.
20. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147:1031-1039. doi: 10.1001/archdermatol.2011.119.
21. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a Prospective Observational Study. Arterioscler Thromb Vasc Biol. 2015;35:2667-2676. doi: 10.1161/ATVBAHA.115.306460.
22. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411-2418. doi: 10.1038/jid.2009.112.
23. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741. doi: 10.1001/jama.296.14.1735.
24. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W; International Psoriasis Council. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010;24:1371-1377. doi: 10.1111/j.1468-3083.2010.03656.x.
25. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000-1006. doi: 10.1093/eurheartj/ehp567.
26. Mehta NN, Krishnamoorthy P, Yu Y, Khan O, Raper A, Van Voorhees A, Troxel AB, Gelfand JM. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67:796-798. doi: 10.1016/j. jaad.2012.05.016.
27. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577.
28. Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenburgh MJ, Schaumberg DA, Lee IM, Glynn RJ, Ridker PM, Buring JE, Mora S. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ Res. 2016;118:1106-1115. doi: 10.1161/CIRCRESAHA.115.308078.
29. Fischer K, Kettunen J, Würtz P, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11:e1001606. doi: 10.1371/journal.pmed.1001606.
30. Jago R, Drews KL, Otvos JD, Willi SM, Buse JB. Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. Int J Obes (Lond). 2016;40:1157-1163. doi: 10.1038/ijo.2016.84.
31. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132:556-562. doi: 10.1038/jid.2011.365.
32. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835. doi: 10.1016/j.jaad.2006.08.040.
33. Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147-157. doi: 10.1111/j.1365-2796.2010.02310.x.
34. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, Lawler MA, Grinspoon SK, Brady TJ, Nasir K, Hoffmann U, Tawakol A. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6:1250-1259. doi: 10.1016/j.jcmg.2013.08.006.
35. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-1620. doi: 10.2967/jnumed.109.065151.
36. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, Tahara N, Fuster V, Warburton EA, Fayad ZA, Tawakol AA. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527-2535. doi: 10.1016/j.jacc.2009.12.061.
37. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, Naruse H, Ishii J, Hishida H, Wong ND, Virmani R, Kondo T, Ozaki Y, Narula J. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57. doi: 10.1016/j.jacc.2009.02.068.
38. Versteylen MO, Kietselaer BL, Dagnelie PC, Joosen IA, Dedic A, Raaijmakers RH, Wildberger JE, Nieman K, Crijns HJ, Niessen WJ, Daemen MJ, Hofstra L. Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome. J Am Coll Cardiol. 2013;61:2296-2305. doi: 10.1016/j.jacc.2013.02.065.